Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the UASAR 2 clinical trial and an Australian community-based series

• Published in: The lancet. Gastroenterology & hepatology 2018
• Main Authors: Domingo, Enric, Camps, C, Kaisaki, Pamela J, Parsons, Marie J, Mouradov, Dmitri, Pentony, Melissa M, Makino, S, Palmieri, Michelle, Ward, Robyn L, Hawkins, Nicholas J, Gibbs, Peter, Askautrud, Hanne Arenberg, Oukrif, Dahmane, Wang, Haitao, Wood, J, Tomlinson, E, Bark, Yasmine, Kaur, Kulvinder, Johnstone, E.C, Palles, Claire, Church, David N, Novelli, Marco, Danielsen, Håvard Emil, Sherlock, Jon, Kerr, David, Kerr, Rachel, Sieber, Oliver, Taylor, JC, Tomlinson, Ian
• Format: Article
• Language: Norwegian
• ISSN: 2468-1253; 2468-1253
• DOI: 10.1016/S2468-1253(18)30117-1

Background: Molecular indicators of colorectal cancer prognosis have been assessed in several studies, but most analyses have been restricted to a handful of markers. We aimed to identify prognostic biomarkers for colorectal cancer by sequencing panels of multiple driver genes. Methods: In stage II or III colorectal cancers from the QUASAR 2 open-label randomised phase 3 clinical trial and an Australian community-based series, we used targeted next-generation sequencing of 82 and 113 genes, respectively, including the main colorectal cancer drivers. We investigated molecular pathways of tumorigenesis, and analysed individual driver gene mutations, combinations of mutations, or global measures such as microsatellite instability (MSI) and mutation burden (total number of non-synonymous mutations and coding indels) for associations with relapse-free survival in univariable and multivariable models, principally Cox proportional hazards models. Findings: In QUASAR 2 (511 tumours), TP53, KRAS, BRAF, and GNAS mutations were independently associated with shorter relapse-free survival (p